Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Quality and cost improvement in neonatal prescribing through clinical audit

Quality and cost improvement in neonatal prescribing through clinical audit Gentamicin is one of the most frequently used antibiotics in neonatal units and there are many regimes in use based on weight and/or gestational age (GA). Direct costs include prescription and therapeutic drug monitoring (TDM). A retrospective audit (loop 1) identified 48 per cent trough and 51 per cent peak levels outside the desirable range (trough: ≤2; peak: 5‐10 mg/L). A prospective re‐audit (loop 2) showed improved results (15 per cent and 29 per cent), which improved further (11 per cent and 26 per cent) in loop 3. For loops 1, 2, and 3 the mean (±SD) trough levels were 2.16 (±1.04), 1.30 (± 0.63) and 1.23 (±0.62) respectively and peak levels were 5.05 (±1.87), 6.64 (±2.48), and 6.2 (±1.81) respectively. Cost savings occurred as the number of doses required was reduced by one‐third to 50 per cent, depending upon the infant characteristics. Furthermore, in 27 per cent of cases, gentamicin was discontinued before TDM was necessary. By completing the audit cycle improved quality of therapeutic care has been achieved, with more accurate drug monitoring targets achieved and reduced drug costs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Governance An International Journal Emerald Publishing

Quality and cost improvement in neonatal prescribing through clinical audit

Loading next page...
 
/lp/emerald-publishing/quality-and-cost-improvement-in-neonatal-prescribing-through-clinical-XArlcvWkjl

References (27)

Publisher
Emerald Publishing
Copyright
Copyright © 2004 Emerald Group Publishing Limited. All rights reserved.
ISSN
1477-7274
DOI
10.1108/14777270410566643
Publisher site
See Article on Publisher Site

Abstract

Gentamicin is one of the most frequently used antibiotics in neonatal units and there are many regimes in use based on weight and/or gestational age (GA). Direct costs include prescription and therapeutic drug monitoring (TDM). A retrospective audit (loop 1) identified 48 per cent trough and 51 per cent peak levels outside the desirable range (trough: ≤2; peak: 5‐10 mg/L). A prospective re‐audit (loop 2) showed improved results (15 per cent and 29 per cent), which improved further (11 per cent and 26 per cent) in loop 3. For loops 1, 2, and 3 the mean (±SD) trough levels were 2.16 (±1.04), 1.30 (± 0.63) and 1.23 (±0.62) respectively and peak levels were 5.05 (±1.87), 6.64 (±2.48), and 6.2 (±1.81) respectively. Cost savings occurred as the number of doses required was reduced by one‐third to 50 per cent, depending upon the infant characteristics. Furthermore, in 27 per cent of cases, gentamicin was discontinued before TDM was necessary. By completing the audit cycle improved quality of therapeutic care has been achieved, with more accurate drug monitoring targets achieved and reduced drug costs.

Journal

Clinical Governance An International JournalEmerald Publishing

Published: Dec 1, 2004

Keywords: Drug administration; Auditing; Cost reduction; Quality

There are no references for this article.